CHICAGO and CAMBRIDGE, Mass., May 31, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced positive results from a Phase 1 clinical trial of IPI-504, the company's lead Hsp90 inhibitor, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) refractory to tyrosine kinase inhibitors. Results from the study showed that patients with GIST (n=36), who were heavily pre-treated, experienced a 70 percent overall disease control rate, with three percent Partial Response and 67 percent Stable Disease at six weeks. Estimated median progression free survival for these patients was 12 weeks. Based on these results, Infinity also announced plans to initiate an international Phase 3 registration trial of IPI-504 in patients with refractory GIST under a Special Protocol Assessment agreement granted by the U.S. Food and Drug Administration (FDA), and pursuant to scientific advice received from the European Medicines Evaluation Agency.
